Value of the consumer healthcare market1
Global categories1
Power Brands
Revenue
Over-the-Counter (OTC)
of 2024 revenue
We focus on premium, specialist Therapeutic Oral Health, with broad geographic presence. Haleon is the global #13 player in Sensitivity with Sensodyne, #23 in gum health with parodontax and #13 in Denture Care.
of 2024 revenue
The VMS category is a large and fast-growing part of the global consumer healthcare market. It is a highly fragmented category, with the top 20 players accounting for around 22%2 of the market. Haleon has the leading position, with 2.8%2 share.
Our key brands include: Centrum, the world’s leading multivitamin2; Caltrate, a leader in bone health in China2; and Emergen-C, a leader in immunity in the US3.
Over-the-Counter (OTC)
of 2024 revenue
At a global level, the top five players account for c.35%2 of the category, and Haleon is the market leader with 13%2 global market share.
Our portfolio spans systemic and topical sub-categories, led by three Power Brands – Voltaren, Panadol and Advil – complemented by Local Growth Brands, including Excedrin, Fenbid and Grand-Pa.
Over-the-Counter (OTC)
of 2024 revenue
The Respiratory Health category is fragmented globally, with the top five players accounting for 26%2 of the market. As at the end of 2023, Haleon had a joint leading position, with 5.6%2 share.
Our portfolio consists of two Power Brands, Otrivin and Theraflu, along with Local Growth Brands, including Flonase, Robitussin and Contac.
Over-the-Counter (OTC)
of 2024 revenue
Haleon has a strong presence in the global Digestive Health category, driven by our leading position in immediate-relief antacids. We have a focused geographic Digestive Health presence across key markets, in particular the US, India and Brazil, underpinned by brands such as Tums and ENO.
1 Source: Nicholas Hall, Euromonitor Passport and Haleon analysis of third-party data (2023), the latest available data for the Consumer Healthcare market as a whole, beyond our individual categories.
2 Definitions and calculations of non-IFRS measures can be found from page 43 in the Annual Report 2024.
3 Oral Health market position refers to Therapeutic Oral Health which comprises c.90% of 2024 Oral Health revenues.
By the numbers
(2023: £11.3bn)
(2023: 4.1%)
(2023: 8.0%)
(2023: £2.0bn)
(2023: 17.7%)
(2023: 9.4%)
(2023: £2.5bn)
(2023: 22.6%)
(2023: 10.8%)
(2023: 11.3p)
(2023: 17.3p)
(2023: 6.0p)
(2023: £2.1bn)
(2023: £1.6bn)
(3.0x as at 31 December 2023)
1 We use certain non-IFRS alternative performance measures to provide additional information about the Company’s performance. Non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. Non-IFRS measures are defined and reconciled to the nearest IFRS measure, see from page 43 in the Annual Report for more details.
2 Includes the interim dividend of 2.0p paid on 19 September 2024, and the proposed final dividend of 4.6p per ordinary share. The total dividend represents a payout ratio of c.37% of adjusted earnings (2023: c.35%).
In 2024, Haleon delivered another year of strong financial performance continuing the trajectory that the business set out following demerger. We have also been proactively managing the portfolio for growth, divesting of ChapStick and the non-US Nicotine Replacement Therapy business, raising proceeds of £0.8bn.
We are driven by our purpose - to deliver better everyday health with humanity.
Our strategy is designed to grow our portfolio of leading brands and market categories. We target sustainable above-market growth and attractive returns, with our purpose and culture bringing focus and clarity to the strategic decisions we make. Underpinning the way we run our business are four strategic pillars.
We have several enterprise metrics monitoring performance across the business, from which we select our key performance indicators.
Measures the strength of our existing portfolio.
Our adjusted operating profit is an important indicator of the strength of our business model.
Provides the business with capacity to invest in the business, pay down debt and make shareholder returns.
Drives value-creating behaviours and captures excess cash returned to shareholders via share buy-backs, which in turn increase total shareholder returns.
The attractiveness of our products is key for all our stakeholders, giving them confidence in our ability to increase household penetration and capitalise on new and emerging opportunities.
1 Organic revenue growth, Organic operating profit growth, Net Debt, Adjusted diluted earnings per share growth and Free cash flow are non-IFRS measures. Definitions and calculations of non-IFRS measures can be found from page 43 in the Annual Report 2024.
2 Haleon portfolio revenue growth in 2020 and 2021 was 4.9% and 3.9% respectively, which illustrates the performance of the brands that made up the portfolio at the time of the demerger.
Health Inclusivity:
people empowered to be more included in opportunities for better everyday health1
Tackling carbon emissions:
reduction in net Scope 1 and 2 carbon emissions vs 20202
Making our packaging more sustainable:
of product packaging recycle-ready3,4
Sourcing trusted ingredients sustainably:
of key materials are sustainably sourced and deforestation free3,5
1 2024 reporting period is 1 December 2023 to 30 November 2024. Where actual data on initiatives contributing to the goal has not been accessible, extrapolations have been applied in a conservative manner to determine indicative results.
2 2024 reporting period is 1 December 2023 to 30 November 2024. The baseline is 1 January 2020 to 31 December 2020.
3 2024 reporting period = 1 July 2023 – 30 June 2024.
4 Recycle-ready means product packaging and devices that are made of materials that are proven to be compatible with existing or emerging recycling infrastructure. In line with the CDP definition of ‘technical recyclability’ this does not take into account whether the collection, sorting, and recycling of the packaging or device happens in practice, at scale, and with reasonable economics.
5 Scope includes Haleon’s globally managed spend on key materials that are agricultural, forest, or marine-derived. Globally managed spend covers the majority of our internal spend and expands across some of our third-party manufacturing network.
*KPMG LLP has issued independent limited assurance over the selected data indicated using assurance standards ISAE(UK)3000 and ISAE 3410. Haleon's reporting criteria are available at www.haleon.com/our-impact/esg-reporting-hub.
From the report
Chair's Statement
(0.24MB, PDF)
CEO's Review
(0.55MB, PDF)
Strategic Report
2.29MB, PDF)
Corporate Governance
(3.07MB, PDF)
Financial Statements
(0.62MB, PDF)
Key Performance Indicators
(0.23MB, PDF)
Online Spreads
(18.79MB, PDF)
Interactive Report
(21.19MB, PDF)
TCFD
(0.10MB, PDF)
Form 20-F
ESEF
(5.5MB, ZIP)
Request a printed Annual Report and Form 20-F 2024.
Related
